Drilldown: Medicines
Appearance
Use the filters below to narrow your results.
None (1) ·
2-FDCK (1) ·
3-HO-PCE (1) ·
3-HO-PCP (1) ·
3-MeO-PCE (1) ·
3-MeO-PCP (1) ·
4-MeO-PCP (1) ·
Amantadine (1) ·
Apomorphine (1) ·
Benztropine (1) ·
Biperiden (1) ·
Bromocriptine (1) ·
Cabergoline (1) ·
Carbidopa/levodopa (1) ·
Deschloroketamine (1) ·
Dextromethorphan (1) ·
Dextrorphan (1) ·
Diphenidine (1) ·
Entacapone (1) ·
Ephenidine (1) ·
Eticyclidine (1) ·
Guaifenesin (1) ·
Ibogaine (1) ·
Levodopa (1) ·
Methoxetamine (1) ·
Nitrous oxide (1) ·
O-PCE (1) ·
Opicapone (1) ·
Rasagiline (1) ·
Rotigotine (1) ·
Safinamide (1) ·
Salvia divinorum (1) ·
Salvinorin A (1) ·
Selegiline (1) ·
Tolcapone (1) ·
Trihexyphenidyl (1) ·
Xenon (1)
None (1) ·
Active metabolite of DXM; NMDA antagonist (1) ·
Central and peripheral COMT inhibitor (1) ·
Contains salvinorin A (1) ·
D1/D2/D3 receptor agonist (1) ·
D2 agonist; D1 partial agonist (1) ·
D2 receptor agonist (1) ·
Dopamine precursor (1) ·
Dopamine precursor + DOPA decarboxylase inhibitor (1) ·
Irreversible selective MAO-B inhibitor (2) ·
Kappa-opioid agonist; NMDA antagonist; SERT/DAT/NET inhibitor (1) ·
Kappa-opioid receptor agonist (1) ·
MAO-B inhibitor; sodium channel blocker; glutamate release inhibitor (1) ·
Muscarinic receptor antagonist (1) ·
Muscarinic receptor antagonist; dopamine reuptake inhibitor (1) ·
NMDA antagonist (3) ·
NMDA antagonist; dopamine releasing agent (1) ·
NMDA antagonist; endogenous opioid releaser (1) ·
NMDA antagonist; fluorinated ketamine analogue (1) ·
NMDA antagonist; kappa-opioid agonist (1) ·
NMDA antagonist; ketamine analogue (1) ·
NMDA antagonist; more stimulating than PCP (1) ·
NMDA antagonist; opioid agonist (1) ·
NMDA antagonist; potent opioid agonist (1) ·
NMDA antagonist; SERT inhibitor; sigma-1 agonist (1) ·
NMDA antagonist; sigma receptor agonist (2) ·
NMDA antagonist; sigma receptor agonist; dopaminergic (1) ·
NMDA antagonist; sigma-1 agonist; serotonin reuptake inhibitor (1) ·
Non-selective dopamine receptor agonist (1) ·
Once-daily COMT inhibitor (1) ·
Peripheral COMT inhibitor (1) ·
Selective M1 muscarinic antagonist (1) ·
'"`UNIQ--vote-0000104D-QINU`"' Adequate hydration is at least as important as the drug in producing the expectorant effect clinically. Used in combination with dextromethorphan, decongestants, or antihistamines in many proprietary OTC cold preparations. (1)
None (35) ·
Treatment-resistant depression (TRD) in adults, as adjunct to oral antidepressant (FDA-approved March 2019). Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (FDA-approved Aug 2020). (1) ·
'"`UNIQ--vote-0000104E-QINU`"', '"`UNIQ--vote-0000104F-QINU`"' (1)
None (35) ·
200-400 mg PO q4h (IR); 600-1200 mg PO q12h (Mucinex 12-Hour ER) (1) ·
Induction (TRD): 56 mg intranasal twice weekly × 4 weeks. Maintenance: 56-84 mg once weekly × 4 weeks, then 56-84 mg every 1-2 weeks. For acute suicidality: 84 mg twice weekly × 4 weeks. Administered under medical supervision in REMS-certified site. (1)
Showing below up to 37 results in range #1 to #37.


